<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210961</url>
  </required_header>
  <id_info>
    <org_study_id>C2501001</org_study_id>
    <nct_id>NCT03210961</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis</brief_title>
  <official_title>A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Anticipated">December 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Combination single and multiple ascending dose design. Cohorts of participants are assigned to receive interventions based on acceptable safety, tolerability, and pharmacokinetics of previous dose cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) up to study day 28 for healthy participants</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline up to study day 28 for healthy participants</time_frame>
    <description>Clinical laboratory assessments include: including hematology, fibrinogen, chemistry, fasting glucose, lipids, urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to study day 28 for healthy participants</time_frame>
    <description>Criteria for ECG abnormalities: maximum PR interval &gt;=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) &gt;=25 percent (%) for baseline value of &gt;200 msec and Pctchg&gt;=50% for baseline value of &lt;=200 msec for PR interval, maximum QRS interval &gt;=140 msec and a maximum IFB: Pctchg&gt;=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to &lt;480 msec, 480 msec to &lt;500 msec or &gt;=500 msec and a maximum change of &lt;=30change&lt;60 or &gt;=60 msec from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Categorical Vital Signs Data</measure>
    <time_frame>Baseline up to study day 28 for healthy participants</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) baseline up to study day 84 for psoriasis participants</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline up to study day 56 for psoriasis participants</time_frame>
    <description>Clinical laboratory assessments include: including hematology, fibrinogen, chemistry, fasting glucose, lipids, urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to study day 56 for psoriasis participants</time_frame>
    <description>Criteria for ECG abnormalities: maximum PR interval &gt;=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) &gt;=25 percent (%) for baseline value of &gt;200 msec and Pctchg&gt;=50% for baseline value of &lt;=200 msec for PR interval, maximum QRS interval &gt;=140 msec and a maximum IFB: Pctchg&gt;=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to &lt;480 msec, 480 msec to &lt;500 msec or &gt;=500 msec and a maximum change of &lt;=30change&lt;60 or &gt;=60 msec from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Categorical Vital Signs Data</measure>
    <time_frame>Baseline up to study day 56 for psoriasis participants</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>Samples for pharmacokinetics collected during the single ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio (Rac)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio for Cmax (Rac Cmax)</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak to Trough Ratio</measure>
    <time_frame>Pre-dose on study days 1, 2, 4, 6, 8, 10, and day 10 at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 168 hours post dose</time_frame>
    <description>Samples collected for pharmacokinetics during the multiple ascending dose period (healthy participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak to Trough Ratio</measure>
    <time_frame>Pre-dose on study days 1, 7, 14, 21, 28, and day 28 at 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Samples for pharmacokinetics collected during once daily dosing for 28 days in psoriasis participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psoriasis area and severity index(PASI)score at Day28</measure>
    <time_frame>Change from baseline at study day 28</time_frame>
    <description>PASI will be performed in psoriasis participants only</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>PF-06826647 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06826647 oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral solution/suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 tablet</intervention_name>
    <description>PF-06826647 tablet for oral administration</description>
    <arm_group_label>PF-06826647 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 oral suspension</intervention_name>
    <description>PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)</description>
    <arm_group_label>PF-06826647 oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo oral solution/suspension</intervention_name>
    <description>placebo oral solution for the single ascending dose, first cohort only</description>
    <arm_group_label>Placebo oral solution/suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Matching placebo tablet</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Participants:

        Inclusion Criteria:

          -  Healthy male subjects between ages of 18-55 years

          -  Healthy female subjects of non-childbearing potential between the ages of 18-55 years

          -  Body Mass Index (BMI) of 17.5 to 30.5kg/m2; and a total body weight &gt;50kg (110lbs).

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential

          -  Fertile male subjects who are unwilling or unable to use a highly effective method of
             contraception as outlined in this protocol for the duration of the study and for at
             least 28days after the last dose of investigational product

          -  Have a clinically significant infection currently or within 6 months of first dose of
             study drug

        Psoriasis Participants:

        Inclusion

          -  Healthy male subjects between ages of 18-65 years

          -  Healthy female subjects of non-childbearing potential between the ages of 18-65 years

          -  Have a diagnosis of plaque psoriasis for at least 6months prior to first study dose

          -  Have plaque-type psoriasis covering at least 15% of total body surface area (BSA) at
             Day-1(prior to randomization in the study

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB) Exclusion

          -  Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular
             psoriasis

          -  Have a clinically significant infection currently or within 6 months of first dose of
             study drug, or a history of chronic or recurrent infectious disease

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential

          -  Fertile male subjects who are unwilling or unable to use a highly effective method of
             contraception as outlined in this protocol for the duration of the study and for at
             least 28days after the last dose of investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Winkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anaheim Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Pfizer CT.gov Call Center, Winkle</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C2501001&amp;StudyName=A+Phase+1%2C+Within+Cohort%2C+Randomized%2C+Double+Blind%2C+Third-party+Open%2C+Placebo-controlled%2C+Single-+And+Multiple+Dose+Escalation%2C+Parallel+Group+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Pf+06700841+In+Healthy+Subjects+And+Subjects+With+Plaque+Psoriasis+And+Bioavailability+Of+A+Tablet+Formulation+Relative+To+Suspension+Formulation+And+The+Effect+Of+Food+On+A+Tablet+Formulation+Of+Pf-06700841</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C2501001&amp;StudyName=A+Phase+1%2C+Within+Cohort%2C+Randomized%2C+Double+Blind%2C+Third-party+Open%2C+Placebo-controlled%2C+Single-+And+Multiple+Dose+Escalation%2C+Parallel+Group+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Pf-06826647+In+Healthy+Subjects+And+Subjects+With+Plaque+Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

